CureDuchenne Release: “CureDuchenne Ventures” Launched to Accelerate Drug Discovery and Development for Duchenne Muscular Dystrophy

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne announced today the launch of CureDuchenne Ventures, a new initiative to identify and develop a robust pipeline of therapies to treat Duchenne, the most common and lethal form of muscular dystrophy. This drug discovery and development initiative is based on CureDuchenne’s successful venture philanthropy model, in which the organization provides early stage funding to biotechnology, pharmaceutical companies and academic investigators to help develop breakthrough therapies to treat Duchenne.

Help employers find you! Check out all the jobs and post your resume.